Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Other solid neoplasm 3Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Other neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1

Conditions

Solid Tumor 1Malignant Neoplasmas 1Advanced Solid Tumors 1

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × ON 01910 × Other solid neoplasm × Clear all
NCT00861328 2017-06-23

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Traws Pharma, Inc.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT01125891 2017-06-23

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
39 enrolled
Other neoplasmOther solid neoplasm

Malignant Neoplasmas

NCT01168011 2017-06-23

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
68 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡